Search

Displaying results 4611 - 4620 of 8172 in total
  1. Drug

    DA-6886

    go.drugbank.com/drugs/DB12853
    Investigational

    DA-6886 has been used in trials studying the treatment of Irritable Bowel Syndrome.

  2. Drug

    Aprepitant

    go.drugbank.com/drugs/DB00673
    ApprovedInvestigational

    Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting … Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Inducers
  3. Drug

    TU-100

    go.drugbank.com/drugs/DB12467
    Investigational

    TU-100 has been used in trials studying the treatment of Abdominal Pain, Colonic Transit, Crohn's Disease, Rectal Sensation, and Gastric Emptying, among others.

  4. Drug

    AR-9281

    go.drugbank.com/drugs/DB06345
    Investigational

    AR-9281 inhibits soluble epoxide hydrolase.

  5. Drug

    Tandamine

    go.drugbank.com/drugs/DB09192
    Experimental

    Tandamine was researched in 1970s as an antidepressant but was never commercialized. Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI).

  6. Drug

    Menaquinone 7

    go.drugbank.com/drugs/DB13075
    Investigational

    Menaquinone 7 is under investigation in clinical trial NCT00402974 (The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children).

    Mixtures: YYUX Organic Liquid Vitamin D3 plus K2 Drops
  7. Drug

    Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen

    go.drugbank.com/drugs/DB16902
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  8. Drug

    Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16903
    ApprovedWithdrawn

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  9. Drug

    Influenza B virus B/Singapore/WUH4618/2021 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16910
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/Darwin/11/2021 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16914
    ApprovedWithdrawn

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen